Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Aslan Pharma OK'd to Start US Arm of Phase II Trial of AML Treatment

publication date: Jan 10, 2019

Aslan Pharma, a Singapore oncology company, announced the US FDA has concluded its 30-day review of Aslan's IND application for ASLAN003. The company plans to evaluate the candidate in the US as part of an ongoing Phase II trial of ASLAN003 in patients with acute myeloid leukemia. Trials are already underway in Singapore and Australia. Aslan believes ASLAN003, an oral inhibitor of DHODH, has the potential to be a first-in-class drug. It has Orphan Drug Designation in the US and Europe. More details....

Stock Symbols: (NSDQ: ASLN, TPEx: 6497)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.